Mobile

A PHASE 2A, DOUBLE BLIND (3RD PARTY OPEN), 4 WAY CROSS-OVER, PLACEBO CONTROLLED STUDY TO INVESTIGATE THE PHARMACOKINETICS, SAFETY, TOLERATION AND EFFICACY OF SINGLE INHALED DOSES OF PF-00610355 IN MOD...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-001396-30

A PHASE 2A, DOUBLE BLIND (3RD PARTY OPEN), 4 WAY CROSS-OVER, PLACEBO CONTROLLED STUDY TO INVESTIGATE THE PHARMACOKINETICS, SAFETY, TOLERATION AND EFFICACY OF SINGLE INHALED DOSES OF PF-00610355 IN MODERATE COPD PATIENTS

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To characterize the single dose pharmacokinetics of inhaled PF-00610355 in COPD patients. • To evaluate the safety & toleration of single inhaled doses of PF-00610355 in COPD patients.

Critère d'inclusion

  • Chronic Obstructive Pulmonary Disease (COPD)

Liens